908848-10-2

Upstream product

• 143615-35-4 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl fluoride 
• 908848-25-9 (2S,3R,4S)-3-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-4-tetradecyl-1-hexacosanoylazetidine 
• 908848-05-5 (2S,3R,4S)-3-(tert-butyldimethylsilyloxy)-2-[(tert-butyldimethylsilyloxy)methyl]-4-tetradecylazetidine 
• 908848-04-4 (2S,3R,4S)-3-(tert-butyldimethylsilyloxy)-2-[(tert-butyldimethylsilyloxy)methyl]-4-tetradecyl-1-(p-toluenesulfonyl)azetidine 
• 908848-06-6 (2S,3R,4S)-3-(tert-butyldimethylsilyloxy)-2-[(tert-butyldimethylsilyloxy)methyl]-4-tetradecyl-1-hexacosanoylazetidine 
• 205371-64-8 N-[(1S,2S,3R)-2-(tert-Butyl-dimethyl-silanyloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-3-hydroxy-heptadecyl]-4-methyl-benzenesulfonamide 

Relevant academic research and scientific papers

NASAL VACCINE

The present invention provides a nasal vaccine capable of intranasally inducing an effective immunity reaction. Specifically, the invention provides a nasal vaccine containing a compound having an NKT cell-activating action, particularly a compound repres

RCAI-8, 9, 18, 19, and 49-52, conformationally restricted analogues of KRN7000 with an azetidine or a pyrrolidine ring: Their synthesis and bioactivity for mouse natural killer T cells to produce cytokines

Conformationally restricted analogues of KRN7000, an α-d-galactosyl ceramide, were synthesized to examine their bioactivity for mouse natural killer (NK) T cells to produce cytokines. RCAI-8, 9, 51, and 52 are the analogues with a pyrrolidine ring, and RC

COMPOUND HAVING CYCLIC STRUCTURE AND USE THEREOF

The present invention relates to a compound represented by the following formula (1') wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a